We are:

  • A Biotechnology Company Specializing in Human Vaccines
  • Creating, Developing, Manufacturing & Testing Innovative AIDS Vaccines
  • Conducting Multiple Site Phase 2 Human Clinical Vaccine Trial

Our AIDS Vaccines:

  • Are Designed for Predominant AIDS Virus Subtypes
  • Use DNA & Viral Vector Technologies
  • Satisfactorily Completed Phase 1 Human Clinical Trial Testing
  • Have Been Proven Safe & Have Demonstrated Ability To Stimulate Immune Responses

Key Market Factors:

  • Vaccines Are The Most Cost Effective Way to Combat Infectious Disease
  • Large Global AIDS Vaccine Market Is Estimated To Be More Than $4 Billion
  • Customer Base Includes All Ages, Genders, Races, Nationalities, Geographical Regions

27 August 2010

Annual Meeting Results

Read full story (pdf) »

06 August 2010

Financial Results & Operational Update

Read full story »

02 August 2010

GeoVax CEO Named to 2010 "PHARMAVOICE 100"

Read full story (pdf) »

28 July 2010

Financing Update

Read full story (pdf) »

22 July 2010

Robinson Interviewed on HealthRadio.net

Read full story (pdf) »

Listen to podcast »

Investor FAQs

Company Fact Sheet (pdf)